Bionano Genomics, Inc. short interest in 2025
In 2025, Bionano Genomics, Inc.'s disclosed short interest ran from 20.09% of shares outstanding on 15 Jan 2025 to 10.29% on 31 Dec 2025, a change of -9.80 percentage points. The year's high was 29.20% on 30 Sep 2025 and its low 7.08% on 29 Aug 2025, averaging 15.89% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.23 days on 13 Jun 2025. Full history: Bionano Genomics, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 20.09% (15 Jan 2025)
- End of year
- 10.29% (31 Dec 2025)
- Change
- -9.80 pp
- High
- 29.20% (30 Sep 2025)
- Low
- 7.08% (29 Aug 2025)
- Average
- 15.89%
- Highest days to cover
- 9.23 (13 Jun 2025)
- SEC filings marked
- 9
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 20.09% | 1.00 | results (8-K) |
| 31 Mar 2025 | 19.55% | 7.80 | 10-K filed, results (8-K) |
| 15 Apr 2025 | 19.87% | 1.86 | |
| 30 Apr 2025 | 16.17% | 5.26 | |
| 15 May 2025 | 19.10% | 3.69 | 10-Q filed, results (8-K) |
| 30 May 2025 | 20.32% | 6.30 | |
| 13 Jun 2025 | 18.26% | 9.23 | |
| 30 Jun 2025 | 16.56% | 5.07 | |
| 15 Jul 2025 | 13.72% | 5.50 | |
| 31 Jul 2025 | 11.06% | 2.73 | |
| 15 Aug 2025 | 8.51% | 4.17 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 7.08% | 1.71 | |
| 15 Sep 2025 | 15.09% | 1.14 | |
| 30 Sep 2025 | 29.20% | 1.00 | |
| 15 Oct 2025 | 22.24% | 1.52 | |
| 31 Oct 2025 | 19.31% | 2.77 | |
| 14 Nov 2025 | 11.27% | 3.15 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 10.77% | 4.26 | |
| 15 Dec 2025 | 9.40% | 4.55 | |
| 31 Dec 2025 | 10.29% | 6.99 |
See also: Bionano Genomics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.